Gene Therapy for Regenerative Medicine
Pharmaceutics · 06.03.2023 · 15 (3) · 856
DOI: 10.3390/pharmaceutics15030856 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 06.03.2023. Verfasst von Hossein Hosseinkhani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center for Advanced Technology, Matrix, Inc., New York, NY 10019, USA. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 350 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The development of biological methods over the past decade has stimulated great interest in the possibility to regenerate human tissues. Advances in stem cell research, gene therapy, and tissue engineering have accelerated the technology in tissue and organ regeneration. However, despite significant progress in this area, there are still several technical issues that must be addressed, especially in the clinical use of gene therapy. The aims of gene therapy include utilising cells to produce a suitable protein, silencing over-producing proteins, and genetically modifying and repairing cell functions that may affect disease conditions. While most current gene therapy clinical trials are based on cell- and viral-mediated approaches, non-viral gene transfection agents are emerging as potentially safe and effective in the treatment of a wide variety of genetic and acquired diseases. Gene therapy based on viral vectors may induce pathogenicity and immunogenicity. Therefore, significant efforts are being invested in non-viral vectors to enhance their efficiency to a level comparable to the viral vector. Non-viral technologies consist of plasmid-based expression systems containing a gene encoding, a therapeutic protein, and synthetic gene delivery systems. One possible approach to enhance non-viral vector ability or to be an alternative to viral vectors would be to use tissue engineering technology for regenerative medicine therapy. This review provides a critical view of gene therapy with a major focus on the development of regenerative medicine technologies to control the in vivo location and function of administered genes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Innovation Center for Advanced Technology, Matrix, Inc., New York, NY 10019, USA.
- The Center for Nanoscience and Nanotechnology, Alex Grass Center for Drug Design and Synthesis and Cannabinoids Research, School of Pharmacy, Faculty of Medicine, Institute of Drug Research, The Hebrew University of Jer…
- Department of Polymer Engineering, School of Chemical Engineering, Universiti Teknologi Malaysia, Skudai 81310, Johor, Malaysia.
ORCID-Profile: Hossein Hosseinkhani, Abraham J Domb
Zitieren
APA
Hosseinkhani, H., Domb, A. J., Sharifzadeh, G., & Nahum, V. (2023). Gene Therapy for Regenerative Medicine. Pharmaceutics, 15(3), 856. https://doi.org/10.3390/pharmaceutics15030856
Vancouver
Hosseinkhani H, Domb AJ, Sharifzadeh G, Nahum V. Gene Therapy for Regenerative Medicine. Pharmaceutics. 2023;15(3):856. doi:10.3390/pharmaceutics15030856
BibTeX
@article{Hosseinkhani2023,
author = {Hosseinkhani, Hossein and Domb, Abraham J and Sharifzadeh, Ghorbanali and Nahum, Victoria},
title = {Gene Therapy for Regenerative Medicine},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {3},
pages = {856},
doi = {10.3390/pharmaceutics15030856}
}
EUVIMED